Academic literature on the topic 'Policystic ovary syndrome'

Background: Polycystic ovary syndrome (PCOS) is a common endocrinopathy in women in reproductive age. It is estimated that it affects about 5-10% of women aged 18-44. This disease is associated with reproductive dysfunction and metabolic disorders. According to the American Society for Reproductive Medicine (ASRM) 2018 guidelines, the first line treatment for PCOS are lifestyle adjustments, including dietary control and exercise. Hence a lot of research on the diet that is most appropriate for this group of people. Material and methods: PubMed research base was searched using the following keywords: diet, pcos, policystic ovary syndrome in 2017-2021. Results: The diet of women with PCOS is poorly composed, and dietary errors may affect the metabolic disorders occurring in these patients. Women with PCOS tend to have insufficient intakes of vitamin D, fiber, and vitamin B9, as well as excessive sodium intake. Mediterranean, ketogenic, low-carbohydrate, low-glycemic, low-AGE and pod-based diets positively affect this disease in various ways. Conclusions: PCOS is a very diverse disease that affects a large number of women around the world. Changing your lifestyle, including diet and exercise, is the first line treatment. This is why creating the best diet for these patients is extremely important. Current discoveries are very promising and give hope to create a model of nutrition that will be the best for these women. Large, multicentre randomized trials are still needed to develop diets that are appropriate for different patients because the disease picture is heterogeneous.

Background/Aim. There are many specificities of merital infertility and sometimes surprising connections between some thinks with no connections at first sight. Examinations of these patients imply diagnostic actions such as the blood basal hormone sample, doing hysterosalpingography, ultrahysterosonography, ultrasound examinations, and sometimes laparoscopy and hysteroscopy if there are necessary. The aim of the study was to determine the characteristics of the connection between policystic ovary (PCO) syndrome (Sy) and congenital M?llerian ducts abnormalities. Methods. This study included 356 patients treated in the period from January 1, to December 31, 2009, in the Department of Infertility of the Clinic for Obstetrics and Gynecology in Nis, Serbia. Exclusion criteria were no myoma, ovary cysts, tubal and male factors of infertility. Results. A total of 180 patients were divided into 3 groups: the group I with PCO sy, the group II with uterine congenital malformation and the group III with a combination of these disorders. The middle age of patients was 29.6 ? 4.8, body mass index (BMI) was 26.1 ? 4,8 kg/m2 the middle thicknes of endometrium was 5.2 + 2.7 mm, and there were no significant differences between the examined groups. There were no significant among in a number of miscarriages in the examined groups. We found that PCO Sy and congenital abnormalities of M?llerian ducts were conjoint in 30% of examined patients. Conclusion. Conjoined PCO Sy and congenital abnormalities of M?llerian ducts do not result in a higher number of misscarriages than only either PCO Sy or abnormalities of M?llerian ducts. It is important to check BMI, basal level of follicle stimulating hormone and number of antral follicles because the induction protocol and concentracion of inductors depends on these characteristics, thus, the successful cycles and pregnancy.

Abstract Polycystic ovary syndrome (PCOS) represent a common endocrine disorder that affects nearly 4 to 12 percents of reproductive age women in general population studies (1). PCOS is caracterized by the oligoovulation or anovulation, hyperandrogenisam and multiple small ovarian cysts. The etiology of PCOS is steel unclear. Patophysiology of PCOS represents the complex mehanism. There is a wide spectar of signs and symptoms of the PCOS, which vary in severity over the time and within individuals. Major symptoms are: the amenhorhea, oligomenorhea combined with of episodes of menometrorhagia. Some signs of hiperandrogenism are: acne, hirsutism and alopecia. Other important symptoms of the PCOS are: the obesity, dyslpedemia, insuline resistance, metabolic syndrome, infertility, endometrial neoplasia, pregnancy loss. Diagnosis is achieved by exclusion of other factors that lead to anovulation, and laboratory assay of sex hormones and gonadotropines. One of the novel approaches in evaluation of etiology and pathogenesis of the PCOS recognizes oxidative stress as an important factor in genesis of this syndrome. For investigation of the oxidative stress role in the pathogenesis of diseases, some biochemical markers have been used including the MDA and NO also anti-oxidative biomarkers such as Total Antioxidative Capacity, Superoxide Dismutase, Glutation Peroxidase, and glutathione. Most of recent studies compared the oxidative stress biomarker level or antioxidative biomarkers levels in the PCOS patients and healthy controls. Patients with the PCOS in those studies were often subdivided in groups by the presence of insulin resistance (HOMA index) or infertility or not. One of the main problems in this field of research is inconsistency in precise definition of the PCOS, as well as different expression of various symptoms within individuals over the time. In that manner it is very difficult to follow up these patients and to establish criteria that could be compared in studies.

INTRODUÇÃO: A metformina tem sido amplamente utilizada no tratamento da síndrome dos ovários policísticos (SOP), porém poucos estudos comparam a metformina e a dieta associada a exercícios físicos. O objetivo deste estudo é comparar parâmetros clínicos e laboratoriais de mulheres com SOP em uso de metformina ou através de dieta e exercícios físicos. MÉTODOS: Foram avaliadas 30 mulheres com SOP, com idades entre 18 a 34 anos, as quais foram divididas em dois grupos: grupo A- tratamento com metformina 1.800mg/dia e grupo B- dieta hipocalórica associada a exercícios físicos. Avaliações clínica e laboratorial foram feitas antes dos tratamentos e a cada três meses, por período de seis meses. RESULTADOS: Não houve diferença significativa entre os tratamentos quanto à regularização do ciclo menstrual (p=0,711), acne (p=0,271), hirsutismo (p=0,146) e índice de massa corpórea (IMC) p=0,328; assim como nas dosagens laboratoriais de LH (p=0,147), FSH (p=0,891), testosterona total (p=0,226) e livre(p=0,455), androstenediona (p=0,066), 17alfa-hidroxiprogesterona (p=0,914), SHBG (p=0,791), colesterol total (p=0,692) e frações, triglicérides (0,291) e nos índices de avaliação de resistência insulínica HOMA-R (p=0,111) e relação glicemia/insulina (p=0,976). Os dois tratamentos apresentaram melhora do ciclo menstrual (76%) e do IMC (p<0,001). A diminuição da circunferência abdominal foi maior no grupo B (p=0,006). CONCLUSÕES: Comparando os dois tratamentos não houve diferença nos parâmetros clínicos e laboratoriais avaliados. Ambos foram eficazes na redução do peso corpóreo e na regularização do ciclo menstrual.<br>Metformin has been widly used in treatment of polycystic ovary syndrome (PCOS) but only few studies compare metformin with diet and exercises. The aim of this study is to compare clinical and laboratorial parameters of women with PCOS using metformin or under diet and exercises. Methods: Thirty women with PCOS were evaluated with ages between 18- 34 years old, who were divided in two groups: group A- treatment with metformin 1.800mg/day and group B- hypocaloric diet and exercises. Clinical and laboratorial evaluations were done before treatment and each three months during a period of six months. RESULTS: There were no significant differences between treatments for menstrual disturbances (p=0,711), acne (p=0,271), hirsutism (p=0,146) and body mass index (BMI), p=0,328; in laboratorial parameters there were no significant differences for LH (p=0,147); FSH (p=0,891), total testosterone (p=0,226), free testosterone (p=0,455), androstenedione (p=0,066), 17alfa-hidroxiprogesterone (p=0,914), SHBG (p=0,791), total cholesterol (p=0,692) and fractions and indexes for evaluation of insulin resitence HOMA-IR (p=0,111) and glycemia and insulin ratio (p=0,976). Both treatments improved menstrual disturbances (76%) and BMI (p<0,001). The abdominal circunference decreasing was greater in group B (p<0,006). CONCLUSIONS: Comparing both treatments there were no differences in clinical and laboratorial parameters evaluated. Both were efficient in improving body mass index and menstrual disturbances.